FORM 4

# **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response.	0.5							

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

10b5-1(c). See Instru	iction 10.							
Name and Address of Reporting Person*     Seth Alpna			2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [ TECH ]		ionship of Reporting Person(s) all applicable) Director	to Issuer		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) $\frac{10/26/2023}{10/26/2023}$		Officer (give title below)	Other (specify below)		
614 MCKINLEY PL N E			4. If Amendment, Date of Original Filed (Month/Day/Year)	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person				
(Street) MINNEAPOLIS	MN	55413			Form filed by More than One			
(City)	(State)	(Zip)						

# Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	, Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price Transaction(s) (Instr. 3 and 4)			(Instr. 4)
Common Stock	10/26/2023		A		1,625	A	\$0	12,309	D	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	Reported		11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Options (Right to Buy)	\$50.41							10/24/2020	10/24/2029	Common Stock	8,044		8,044	D	
Stock Options (Right to Buy)	\$63.92							10/28/2021	10/29/2030	Common Stock	6,028		6,028	D	
Stock Options (Right to Buy)	\$128.81							10/27/2022	10/28/2031	Common Stock	2,532		2,532	D	
Stock Options (Right to Buy)	\$73.94							10/26/2023	10/27/2032	Common Stock	3,460		3,460	D	
Stock Options (Right to Buy)	\$61.51	10/26/2023		A		3,937		(1)	10/26/2033	Common Stock	3,937	\$0	3,937	D	

## **Explanation of Responses:**

1. The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders.

#### Remarks

On November 28, 2022, the Company completed a four-for-one stock split. All common stock amounts and exercise prices in the filing relating to securities acquired prior to November 28, 2022 have been adjusted to reflect the four-for-one stock split.

/s/ Andrew Nick as Attorney-in-Fact for Alpna Seth pursuant to Power of Attorney previously filed.

\*\* Signature of Reporting Person

10/30/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.